MULTI-DOSE DRY POWDER INHALER: ADVANCE TECHNOLOGY FOR DRUG DELIVERY TO AIRWAYS
Journal: Indian Drugs (Vol.56, No. 11)Publication Date: 2019-11-28
Authors : Mehta P.;
Page : 59-62
Keywords : E-mail: piyu053@gmail.com;
Abstract
Multi-dose dry powder inhaler (M-DPI) is a unique inhaler device from Teva Pharmaceutical developed for treatment of chronic respiratory diseases. It is a metered-dose dry powder inhaler system designed to appear as a typical pressurized metered-dose inhaler, but its internal geometry is very unique. The formulation of the inhaled corticosteroid and long-acting β2 agonist in M-DPI has been approved for use in the United States (US) [RespiClick®] and European Union (EU) [Spiromax®] as a treatment for asthma and chronic obstructive pulmonary disease (COPD). This M-DPI is easy to handle and does not need coordination between dose actuation and inhalation. The unique design of M-DPI ensures patients receive consistent doses of the drug with each actuation. The present article is a comprehensive account of the M-DPI with special emphasis on its dose metering system, deagglomeration mechanism and clinical outcomes.
Other Latest Articles
- EFFECT OF GLUCOCORTICOIDS EXPOSURE ON SERUM OSTEOCALCIN LEVELS
- A STUDY TO ASSESS THE LEVEL OF ANXIETY AMONG CLIENTS UNDERGOING UPPER GASTRO ENDOSCOPY AT INDIRA GANDHI GOVT. GENERAL HOSPITAL & POST GRADUATE INSTITUTE , PUDUCHERRY
- AMELIORATION IN INSULIN RESISTANCE AND Β-CELL FUNCTION BY DPP-4 INHIBITION POTENTIAL OF TRIGONELLA FOENUM SEED EXTRACT IN TYPE-2 DIABETIC RATS
- A VALIDATED HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHIC METHOD FOR LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE IN COMBINATION
- METHOD DEVELOPMENT, VALIDATION AND PLASMA ANALYSIS OF ETORICOXIB USING LC-MS/MS IN INDIAN HEALTHY HUMAN VOLUNTEERS
Last modified: 2020-01-11 20:23:37